Genetic score may sharpen heart risk prediction for millions
NCT ID NCT07039123
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This trial tests whether adding a polygenic risk score (a DNA-based estimate of heart disease risk) to standard risk assessment helps better identify who needs preventive measures like statins or lifestyle changes. About 205 adults aged 40–69 with intermediate cardiovascular risk will either receive standard risk information or have their risk refined with the genetic score. Researchers will compare changes in risk scores and preventive actions over 18 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Polygenic Risk Score for Coronary Artery Disease (PRS-CAD)
What this could lead to
If successful, this approach could help doctors identify who truly needs preventive treatments like statins, reducing heart attacks in people at intermediate risk.
What could go wrong
The trial is relatively small (205 participants) and focuses on risk prediction, not direct treatment. The added value of PRS over standard risk tools may be modest, and results may not apply to all populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Fribourgeois (HFR)
Fribourg, Switzerland
-
University of Bern, Institute of Primary Health Care (BIHAM)
Bern, 3012, Switzerland